Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets
BD Johnson, EE Becker, RL Truitt - Biology of Blood and Marrow …, 1999 - tctjournal.org
Infusions of donor leukocytes have been given to allogeneic bone marrow recipients after
transplant to treat leukemia relapse. Treatment with these delayed infusions of donor cells
has been called delayed or donor leukocyte infusion (DLI). While graft-vs.-host disease
(GVHD) has typically been less severe than expected after DLI, it still remains a significant
risk factor. Recently, we used a full major histocompatibility complex (MHC)-mismatched
model (C57BL/6 into AKR) to determine how increased immunogenetic disparity affects …
transplant to treat leukemia relapse. Treatment with these delayed infusions of donor cells
has been called delayed or donor leukocyte infusion (DLI). While graft-vs.-host disease
(GVHD) has typically been less severe than expected after DLI, it still remains a significant
risk factor. Recently, we used a full major histocompatibility complex (MHC)-mismatched
model (C57BL/6 into AKR) to determine how increased immunogenetic disparity affects …